Two-Pronged Intracellular Co-Delivery of Antigen and Adjuvant for Synergistic Cancer Immunotherapy

Two-Pronged Intracellular Co-Delivery of Antigen and Adjuvant for Synergistic Cancer Immunotherapy

© 2022 Wiley-VCH GmbH.

Bibliographische Detailangaben
Veröffentlicht in:Advanced materials (Deerfield Beach, Fla.). - 1998. - 34(2022), 21 vom: 09. Mai, Seite e2202168
1. Verfasser: Meng, Junli (VerfasserIn)
Weitere Verfasser: Zhang, Peisen, Chen, Qizhe, Wang, Zihua, Gu, Yuan, Ma, Jie, Li, Wang, Yang, Chen, Qiao, Yuanyuan, Hou, Yi, Jing, Lihong, Wang, Yong, Gu, Zi, Zhu, Lichong, Xu, Haozhen, Lu, Xueguang, Gao, Mingyuan
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2022
Zugriff auf das übergeordnete Werk:Advanced materials (Deerfield Beach, Fla.)
Schlagworte:Journal Article CpG cancer immunotherapy iron oxide nanoparticles membrane fusion nanovaccines Adjuvants, Immunologic Antigens Peptides
Beschreibung
Zusammenfassung:© 2022 Wiley-VCH GmbH.
Nanovaccines have emerged as promising alternatives or complements to conventional cancer treatments. Despite the progresses, specific co-delivery of antigen and adjuvant to their corresponding intracellular destinations for maximizing the activation of antitumor immune responses remains a challenge. Herein, a lipid-coated iron oxide nanoparticle is delivered as nanovaccine (IONP-C/OLP) that can co-deliver peptide antigen and adjuvant (CpG DNA) into cytosol and lysosomes of dendritic cells (DCs) through both membrane fusion and endosome-mediated endocytosis. Such two-pronged cellular uptake pattern enables IONP-C/O@LP to synergistically activate immature DCs. Iron oxide nanoparticle also exhibits adjuvant effects by generating intracellular reactive oxygen species, which further promotes DC maturation. IONP-C/O@LP accumulated in the DCs of draining lymph nodes effectively increases the antigen-specific T cells in both tumor and spleen, inhibits tumor growth, and improves animal survival. Moreover, it is demonstrated that this nanovaccine is a general platform of delivering clinically relevant peptide antigens derived from human papilloma virus 16 to trigger antigen-specific immune responses in vivo
Beschreibung:Date Completed 27.05.2022
Date Revised 27.05.2022
published: Print-Electronic
Citation Status MEDLINE
ISSN:1521-4095
DOI:10.1002/adma.202202168